Edwards Lifesciences Earnings Call Transcripts
Fiscal Year 2026
-
Q2 sales grew 12.5% year-over-year, driven by strong performance in TAVR, TMTT, and surgical segments. Full-year 2026 sales and EPS guidance were raised, with robust adoption of new therapies and continued margin expansion expected.
-
Strong Q1 results and increased guidance reflect broad-based growth in TAVR, surgical, and TMTT segments, supported by new clinical evidence and product innovation. Leadership changes and a robust pipeline position the company for sustained double-digit growth and margin improvement through 2027 and beyond.
-
Q1 2026 saw 12.7% sales growth, driven by strong TAVR, TMTT, and Surgical performance, prompting raised full-year guidance for sales and EPS. Robust clinical evidence, innovation, and favorable market dynamics support continued growth across all segments.
-
Momentum in 2025 was driven by strong clinical data for TAVR and expanded mitral/tricuspid solutions, with 2026 growth guided at 6%-8%. Key clinical readouts and next-generation device launches are expected to support future growth, while margin expansion and focused R&D investment remain priorities.
-
The conference highlighted a strategy centered on double-digit organic growth, driven by innovation in TAVR, TMTT, and heart failure therapies. Clinical evidence, such as the EARLY TAVR trial, supports market expansion, while operational investments balance sustainable growth and margin improvement.
-
Leadership transitions are underway with a strong internal bench, while the TAVR franchise benefits from robust clinical data and expanding indications. Financial guidance points to margin expansion and significant growth in the TMDT business, supported by ongoing product innovation and regulatory developments.
-
Leadership changes, strong TAVR growth, and new product launches are shaping the outlook, with regulatory updates and clinical trial data expected to drive further momentum. Recent acquisitions and a focus on innovation support long-term growth, while guidance remains confident for 2026 and beyond.
-
The conference highlighted a robust innovation pipeline in structural heart therapies, strong financial performance, and a clear focus on expanding patient access through next-generation products and regulatory support. Multiple catalysts are set to drive double-digit growth through 2030.
Fiscal Year 2025
-
Q4 and full-year 2025 saw double-digit sales growth, driven by strong TAVR and TMTT performance, new product launches, and strategic investments in patient access. 2026 guidance for 8%-10% sales growth and EPS of $2.90-$3.05 was reaffirmed, with continued margin expansion expected.
-
The company is positioned for 8%-10% sales growth in 2025, driven by TAVR, mitral, and tricuspid therapies, with double-digit EPS growth expected from 2026. Major catalysts include new clinical evidence, expanded indications, and global product launches, targeting 10% average annual growth long term.
-
Q3 2025 saw double-digit sales growth, driven by strong TAVR, TMTT, and surgical performance, with raised full-year guidance for sales and EPS. New clinical data and updated guidelines are fueling adoption, while FX and litigation remain key considerations.
-
Seven-year and ten-year data confirm TAVR's durability and equivalence to surgery, with new devices like SAPIEN 3 Ultra RESILIA and EVOQUE showing improved outcomes. The ENCIRCLE trial marks a milestone in mitral valve replacement, and ongoing innovation is expected to drive significant growth in valve therapies.
-
Q2 2025 saw double-digit sales growth and raised full-year guidance, driven by strong TAVR, TMTT, and surgical performance. Key product approvals, robust clinical data, and global expansion support a positive outlook, with continued margin expansion and innovation investments.
-
Strong financial performance and guidance are supported by resilient supply chain and flexible P&L management. Major growth catalysts include early TAVR approval, robust TMTT expansion, and strategic acquisitions, with regulatory and guideline changes expected to drive multi-year growth.
-
Q1 sales rose 8% to $1.41B, with strong TAVR and TMTT growth and key milestones achieved. Full-year sales and EPS guidance were reaffirmed, with plans to offset tariff and acquisition headwinds. TMTT guidance was raised, and new product launches and clinical data support multi-year growth.
-
Zoom is pivoting from a meetings-focused brand to a comprehensive work platform, emphasizing AI integration, monetization in high-value areas, and disciplined financial management. Growth will be driven by platform expansion, targeted M&A, and innovation in pricing and customer experience.
-
The company is focused on structural heart therapies, with TAVR and TMTT as key growth drivers. Margin expansion is expected from 2026, and new technologies like EVOQUE and PASCAL are set to expand market opportunities. Multi-source growth and strong capital allocation support a 10% organic revenue growth target.
-
The session highlighted a robust innovation strategy focused on structural heart disease, with major growth expected from TAVR, mitral, and tricuspid therapies. Financial guidance projects 8%-10% revenue growth in 2025 and double-digit EPS growth beyond, supported by ongoing R&D and targeted acquisitions.
Fiscal Year 2024
-
2024 sales grew 9% to $5.4B, with TMTT outperforming and TAVR steady. 2025 guidance targets 8%-10% sales growth, led by TAVR, TMTT, and Surgical, with operating margin expansion and robust cash reserves. Strategic acquisitions and new product launches position for long-term growth.
-
Revised summary: The event outlined a strategy for breakthrough innovation in structural heart disease, with growth in TAVR, mitral, and tricuspid therapies, plus heart failure and AR. Financial guidance targets 8%-10% growth in 2025 and 10%+ annually, supported by clinical evidence, new products, and investments. Capacity and AI adoption are key challenges and opportunities.
-
TRISCEND II demonstrated that transcatheter tricuspid valve replacement offers high technical success, significant quality of life improvements, and elimination of regurgitation for most patients. Strong demand and efficient procedures support rapid adoption, while ongoing product iterations and data collection aim to further optimize outcomes.
-
EARLY TAVR trial data show a 50% reduction in major adverse events for asymptomatic severe AS patients treated early, challenging current watchful waiting guidelines. The findings are expected to expand the TAVR market by at least 20-40% and drive rapid adoption ahead of formal guideline changes.
-
Q3 sales grew 10% year-over-year, led by TAVR and TMTT, with adjusted EPS and margins above expectations. Guidance for 2024 remains unchanged, with one-time Q4 impacts anticipated. Strategic acquisitions and product launches position the company for continued growth.
-
Management reaffirmed strategic focus on structural heart disease, highlighted recent acquisitions as long-planned, and expects 2025 EPS to be lower before resuming growth in 2026. TAVR and TMTT remain key growth drivers, with new clinical data and regulatory milestones anticipated to boost adoption.
-
Q2 sales grew 8% year-over-year to $1.6B, with TAVR growth below plan but TMTT up 75%. Guidance for TAVR was lowered to 5%-7% growth, while TMTT guidance was raised. Two acquisitions expand into AR and heart failure, and the Critical Care sale is set to close in Q3.
-
Management detailed the strategic sale of the critical care business to focus on structural heart, highlighted robust growth in TAVR and TMTT, and previewed upcoming clinical trial data that could expand patient access. New product launches and heart failure initiatives are set to drive future growth.
-
The conference highlighted a sharpened focus on structural heart therapies, with TAVR and TMTT as key growth drivers. New product launches, expanding clinical evidence, and strong market adoption—especially for SAPIEN 3 Ultra RESILIA and EVOQUE—are fueling optimism for continued growth.